Background: Using the Cyberonics registry, Amar and colleagues reported poorer efficacy of vagus nerve stimulation (VNS) in patients who failed intracranial epilepsy surgery (IES).
Objective: To study the impact of failed IES and other surrogate marker of severe epilepsy on VNS effectiveness in a large cohort with treatment-resistant epilepsy (TRE).
Methods: We retrospectively reviewed 376 patients (188 female patients; 265 adults; mean age, 29.4 years at implantation) with TRE who underwent VNS implantation between 1997 and 2008 and had at least 1 year of follow-up. One hundred ten patients (29.3%) had failed ≥ 1 prior craniotomies for TRE, and 266 (70.7%) had no history of IES.
Results: The mean duration of VNS therapy was 5.1 years. Patients with prior IES were more commonly male and adult, had a greater number of seizure types, and more commonly had focal or multifocal vs generalized seizures (P < .05). There was no significant difference in the mean percentage seizure reduction between patients with and without a history of IES (59.1% vs 56.5%; P = .42). There was no correlation between type of failed IES (callosotomy vs resection) and seizure reduction with VNS therapy.
Conclusion: Failed IES did not affect the response to VNS therapy. Unlike prior reports, patients with callosotomy did not respond better than those who had resective surgery. Nearly 50% of patients experienced at least 50% reduction in seizure frequency. For patients with TRE, including patients who failed cranial epilepsy surgeries, VNS should be considered a palliative treatment option.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1227/NEU.0b013e3182230ae3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
J Med Virol
December 2024
SR Sanjeevani Hospital, Kalyanpur, Siraha, Nepal.
Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.
View Article and Find Full Text PDFComparative Outcomes of Monopolar and Bipolar Transurethral Resection of the Prostate: An Institutional Perspective.
Cureus
August 2024
Department of General Surgery, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune, IND.
Article Synopsis
- The study aimed to compare two methods of transurethral resection of the prostate—monopolar (M-TURP) and bipolar (B-TURP)—in treating benign prostatic hyperplasia (BPH) among 100 patients.
- Participants were evaluated pre- and post-operatively based on several factors including urinary flow rate, prostate volume, and serum levels, while excluding those with prostate cancer.
- Results indicated that the mean age for surgery was in the sixth decade of life, with both groups showing similar prostate-specific antigen levels and common symptoms such as poor urinary stream and nocturia.
A Comparative Study of Fetal and Maternal Outcomes in Registered and Unregistered Antenatal Cases in a Tertiary Care Center.
Cureus
August 2024
Obstetrics and Gynecology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Background Antenatal care plays a crucial role in ensuring optimal maternal and neonatal health outcomes. However, disparities in access to prenatal care persist, with a subset of pregnant women failing to register for antenatal care, referred to as "unbooked" or "unregistered" pregnancies. This study aims to investigate the impact of registration status on pregnancy outcomes, considering various demographic, clinical, and socioeconomic factors.
View Article and Find Full Text PDFEV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.
J Control Release
October 2024
Department of Innovative Technologies in Medicine & Dentistry, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy. Electronic address:
MYC is one of the most important therapeutic targets in human cancer. Many attempts have been made to develop small molecules that could be used to curb its activity in patients, but most failed to identify a suitable direct inhibitor. After years of preclinical characterization, a tissue-penetrating peptide MYC inhibitor, called Omomyc, has been recently successfully used in a Phase I dose escalation study in late-stage, all-comers solid tumour patients.
View Article and Find Full Text PDFPractical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
Epilepsia Open
October 2024
Goethe-University Frankfurt, Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Article Synopsis
- Fenfluramine is a medicine used to help control seizures in kids and adults with two conditions called Dravet syndrome and Lennox-Gastaut syndrome.
- Doctors have found that it works well for these seizures, especially when other treatments haven't worked.
- This review shares stories of four patients and gives doctors advice on using fenfluramine safely, including possible side effects and how to manage the treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!